Sun Yaohui, Li Yanwen, Exley Rachel M, Winterbotham Megan, Ison Catherine, Smith Harry, Tang Christoph M
Centre for Molecular Microbiology and Infection, Faculty of Medicine, Imperial College London, Armstrong Road, London SW7 2AZ, UK.
Vaccine. 2005 Jul 14;23(32):4136-41. doi: 10.1016/j.vaccine.2005.03.015. Epub 2005 Apr 14.
Systemic infection with Neisseria meningitidis leads to a devastating, septicaemic illness with a high mortality, particularly in children. Currently, there are no vaccines to prevent disease caused by strains of N. meningitidis serogroup B, the commonest isolate in developed countries. Here, we describe the identification of vaccine candidates that protect mice against lethal challenge with this bacterium. A total 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect animals against live bacterial challenge; the lactate permease (LctP) and ExbB, which is required for iron acquisition, elicited protective immunity. Both LctP and ExbB are expressed by a wide range of pathogenic isolates of N. meningitidis. Targeting bacterial factors required for pathogenesis may lead to new vaccines to protect individuals from this important human pathogen.
脑膜炎奈瑟菌的全身感染会引发一种毁灭性的败血症疾病，死亡率很高，尤其是在儿童中。目前，尚无疫苗可预防由B群脑膜炎奈瑟菌菌株引起的疾病，该菌株是发达国家最常见的分离株。在此，我们描述了能够保护小鼠抵御该细菌致死性攻击的候选疫苗的鉴定。总共11种对于建立全身感染必需的脑膜炎球菌蛋白被表达为重组抗原，并评估它们保护动物抵御活细菌攻击的能力；乳酸通透酶（LctP）和获取铁所需的ExbB引发了保护性免疫。LctP和ExbB均由多种致病性脑膜炎奈瑟菌分离株表达。靶向发病机制所需的细菌因子可能会催生新疫苗，以保护个体免受这种重要人类病原体的侵害。
